Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.

Autor: Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Machidori A; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Abe T; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Monji K; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Kashiwagi E; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Takeuchi A; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Takahashi R; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Inokuchi J; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Yokomizo A; Department of Urology, Harasanshin Hospital, Fukuoka, Japan., Naito S; Department of Urology, Harasanshin Hospital, Fukuoka, Japan., Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Jazyk: angličtina
Zdroj: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2020 Dec; Vol. 27 (12), pp. 1109-1115. Date of Electronic Publication: 2020 Sep 15.
DOI: 10.1111/iju.14366
Abstrakt: Objectives: To assess the impact of antiandrogen withdrawal syndrome after bicalutamide withdrawal in castration-resistant prostate cancer patients treated with androgen receptor-axis targeted agents.
Methods: The study cohort comprised 94 patients treated with abiraterone (n = 34) or enzalutamide (n = 60) as a first-line androgen receptor-axis targeted agent for castration-resistant prostate cancer despite combined androgen blockade by castration with bicalutamide as the first-line therapy. The association between clinicopathological factors (including antiandrogen withdrawal syndrome) and therapeutic outcome after using abiraterone and enzalutamide was investigated.
Results: The decline in the prostate-specific antigen level after use of abiraterone or enzalutamide was comparable between patients with and without antiandrogen withdrawal syndrome. Antiandrogen withdrawal syndrome (hazard ratio 3.84, 95% confidence interval 1.29-11.45; P = 0.016) was associated with a higher risk of progression on multivariate analysis, but not all-cause death after abiraterone use. Progression-free survival and overall survival after enzalutamide use did not differ between patients with and without antiandrogen withdrawal syndrome.
Conclusions: The present data suggest a modest therapeutic efficacy of abiraterone in castration-resistant prostate cancer patients with anti-androgen withdrawal syndrome after bicalutamide withdrawal.
(© 2020 The Japanese Urological Association.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje